Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Vortioxetine hydrobromide

Vortioxetine hydrobromide
Contact us for more batch information
Select Batch
Purity:100%
Resource Download

Vortioxetine hydrobromide

Catalog No. T2395LCas No. 960203-27-4
Vortioxetine hydrobromide (Lu AA21004 hydrobromide) is a serotonin (5-HT) modulator and stimulator (SMS), inhibits 5-HT1A/1B/3A/7 receptor and SERT (IC50: 15/33/3.7/19/1.6 nM).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
10 mg$43In Stock
25 mg$58In Stock
50 mg$89In Stock
100 mg$126In Stock
200 mg$197In Stock
500 mg$369In Stock
1 g$531In Stock
1 mL x 10 mM (in DMSO)$38In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Vortioxetine hydrobromide"

Product Introduction

Bioactivity
Description
Vortioxetine hydrobromide (Lu AA21004 hydrobromide) is a serotonin (5-HT) modulator and stimulator (SMS), inhibits 5-HT1A/1B/3A/7 receptor and SERT (IC50: 15/33/3.7/19/1.6 nM).
In vitro
Subcutaneous injection of Lu AA21004 (2.5-10.0 mg/kg) into the medial prefrontal cortex and ventral hippocampal area of rats was found to elevate extracellular levels of 5-HT, DA, and NA. A specific dose of Lu AA21004 (5 mg/kg) targeting the rats’ ventral hippocampal region resulted in a 200% increase in extracellular 5-HT levels. Additionally, administration of Lu AA21004 (at doses of 5 and 10 mg/kg) showed a significant elevation in ACh levels to 224% and 204% respectively, 20 minutes post-injection. This compound, when administered to the ventral hippocampal area of awake rats at doses of 5 and 10 mg/kg, enhanced extracellular 5-HT levels, and a 3-day treatment of the medial prefrontal cortex with Lu-AA21004 (at 5 and 10 mg/kg) substantially raised the basal levels of 5-HT. Furthermore, Lu AA21004 (10 mg/kg) notably decreased pain perception in rats. In terms of pharmacokinetics within rats, Lu-AA21004 exhibited a liver clearance rate of 7.1 (L/h)/kg and an oral bioavailability of 16%. Lastly, Lu AA21004 dose-dependently affected the rats' Bezold-Jarisch reflex by inhibiting transient bradycardia (ED50: 0.11 mg/kg).
In vivo
Lu AA21004 acts as an agonist for the h5-HT1B receptor, with an EC50 value of 460 nM and demonstrating 22% intrinsic activity in whole-cell assays. It inhibits recombinant human cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2D6, and CYP3A4 with IC50 values of 40 μM, 39 μM, 9.8 μM, and 10 μM, respectively. Furthermore, Lu AA21004 binds to the r5-HT7 receptor with a Ki value of 200 nM in vitro whole-cell cAMP assays and functions as a competitive antagonist with an IC50 of 2 μM.
Kinase Assay
Assay of MEK Kinase Activity: Anti-MEK1 antibody is used to immunoprecipitate MEK1 molecules. MEK kinase activity is measured as the ability of immuno-isolated MEK1 to activate recombinant ERK1 in a coupled assay using MBP as the end point of the assay. Phosphorylated MBP is resolved on a 14% SDS-PAGE gel and vacuum-dried before exposure to X-ray film.
AliasVortioxetine (Lu AA21004) HBr, Vortioxetine HBr, Lu AA21004 hydrobromide
Chemical Properties
Molecular Weight379.36
FormulaC18H22N2S·HBr
Cas No.960203-27-4
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 14 mg/mL (36.9 mM)
DMSO: 45 mg/mL (118.62 mM)
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
1 mM2.6360 mL13.1801 mL26.3602 mL131.8009 mL
5 mM0.5272 mL2.6360 mL5.2720 mL26.3602 mL
10 mM0.2636 mL1.3180 mL2.6360 mL13.1801 mL
20 mM0.1318 mL0.6590 mL1.3180 mL6.5900 mL
DMSO
1mg5mg10mg50mg
50 mM0.0527 mL0.2636 mL0.5272 mL2.6360 mL
100 mM0.0264 mL0.1318 mL0.2636 mL1.3180 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords